Company Profile
SELLAS Life Sciences Group, Inc. Stock Price, News & Catalysts
- Ticker:
- SLS
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
14.86 USD (-17.21%)
Close
Last updated: November 19, 2026
1.55B USD
Market cap
Why the stock is moving
The latest monitored company update is âSELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwritersâ Option to Purchase Additional Shares.â The corresponding closing-price reaction is not yet available.
Company overview
Late-Stage Oncology Company
SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor.
Galinpepimut-S
Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is expressed across multiple blood cancers and solid tumors, creating potential for both monotherapy and combination development.
REGAL Phase 3 Program
The Phase 3 REGAL trial evaluates GPS as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line salvage treatment. The event-driven study will proceed to final analysis after the prespecified 80th event.
SLS009
SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity. SELLAS is evaluating the candidate in newly diagnosed frontline AML and preparing for potential clinical development in pancreatic cancer.
Future catalysts
- Topline primary-endpoint results from the Phase 3 REGAL study of galinpepimut-S in November 2026.
- Preliminary topline data from the Phase 2 frontline-AML study of tambiciclib in the fourth quarter of 2026.
- Presentation of completed Phase 2 relapsed/refractory AML data for tambiciclib at ASH on December 12â15, 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. (SLS) most recently closed at 14.86 USD, a -17.21% move versus the previous session.
What is the market cap of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. currently has a market capitalization of 1.55B USD on BioPharmSignal.
What does SELLAS Life Sciences Group, Inc. do?
Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor. Galinpepimut-S Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is...
On which exchange is SLS stock listed?
SELLAS Life Sciences Group, Inc. (SLS) is associated with NASDAQ, United States, Life Science Tools.
What is tambiciclib?
Preliminary topline data from the Phase 2 frontline-AML study of tambiciclib in the fourth quarter of 2026.
Which conditions is SELLAS Life Sciences Group, Inc. targeting with tambiciclib?
SELLAS Life Sciences Group, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does SELLAS Life Sciences Group, Inc. describe recent progress with tambiciclib?
Preliminary topline data from the Phase 2 frontline-AML study of tambiciclib in the fourth quarter of 2026.
What is Late-Stage?
Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors.
